We are live on
!
Find out more
GCGM
General Catalyst Group Management Portfolio holdings
AUM
$184M
1-Year Est. Return
50.45%
This Fund
S&P 500
This Quarter
Est. Return
+28.14%
1 Year Est. Return
+50.45%
3 Year Est. Return
+205.57%
5 Year Est. Return
+78.87%
10 Year Est. Return
–
AUM
$1.27B
AUM Growth
+$219M
(+21%)
Cap. Flow
-$51.1M
Cap. Flow
% of AUM
-4.01%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
–
Reduced
3
Closed
1
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oscar Health
OSCR
|
+$31.6M |
| 2 |
GitLab
GTLB
|
+$10.1M |
| 3 |
Lemonade
LMND
|
+$9.37M |
| 4 |
CZOO
Cazoo Group Ltd
CZOO
|
+$69 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 85.78% |
| 2 | Healthcare | 7.79% |
| 3 | Industrials | 4.01% |
| 4 | Consumer Discretionary | 2.28% |
| 5 | Financials | 0.14% |
Similar funds
IFPL
MIM
EFIC
SWMG
AAM
RFG
KWM
NAM
General Catalyst Group Management's Q4 2023 Portfolio in Review
As of Q4 2023, General Catalyst Group Management held 11 positions worth $1.27B, up 21% from $1.05B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
General Catalyst Group Management withdrew a net $51.1M in Q4 2023, closing 1 position and reducing 3 holdings. Its most notable exit was Lemonade, an estimated $9.37M position sold in full.
By sector, the portfolio is most concentrated in Technology at 86% of assets, up from 80% a quarter earlier, followed by Healthcare and Industrials.
- General Catalyst Group Management's biggest Q4 2023 reduction was Oscar Health, cutting an estimated $31.6M.
- General Catalyst Group Management fully exited Lemonade in Q4 2023, selling an estimated $9.37M.
- General Catalyst Group Management's ten largest holdings make up 100% of its $1.27B portfolio in Q4 2023.
- General Catalyst Group Management opened 0 new positions and closed 1 in Q4 2023.
- General Catalyst Group Management's portfolio value rose 21% quarter-over-quarter to $1.27B.
Based on General Catalyst Group Management's 13F filing for Q4 2023, filed 9 Feb 2024.